Research and Markets: The Ovarian Cancer Therapeutics Market is Poised to Witness Three-Fold Growth until 2020 - Global Drug Forecasts and Treatment Analysis 2020

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/c2ndz3/ovarian_cancer_the) has announced the addition of GlobalData's new report "Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020" to their offering.

GlobalData, the industry analysis specialist, has released its new report, Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020. The report is an essential source of information and analysis on the global ovarian cancer therapeutics market. The report provides comprehensive information on ovarian cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global ovarian cancer therapeutics market. It analyses the treatment usage patterns in the global ovarian cancer therapeutics market.

The Ovarian Cancer Therapeutics Market is Poised to Witness Three-Fold Growth until 2020

The ovarian cancer therapeutics market grew at a Compound Annual Growth Rate (CAGR) of only 1.0% between 2002 and 2011. The patent expires of major branded products, such as Taxol (paclitaxel), Paraplatin (carboplatin), Gemzar (gemcitabine), Hycamtin (topotecan hydrochloride) and the subsequent launch of generics, have acted as restraining factors to the market. The introduction of new and promising therapies such as Avastin (bevacizumab), AMG 386, EC145, Farletuzumab (MORAb-003), Karenitecin (BNP1350), OPAXIO (paclitaxel poliglumex), OPT-821, Paclical (paclitaxel), Vargatef (BIBF 1120) and Votrient (pazopanib) are expected to drive the market from 2011-2020.

In 2011, the ovarian cancer therapeutics markets in key countries (the US, the UK, Germany, France, Italy, Spain, Japan, Brazil, Russia, India and China) were worth $736.7m collectively. The ovarian cancer therapeutics market is expected to witness three-fold growth by 2020, reaching $2,352m at a CAGR of 13.8%. This high growth rate is expected due to the strength of the pipeline candidates, which are anticipated to change the treatment paradigm of ovarian cancer when launched.

Key Topics Covered:

1 List of Tables and Figures

2 Ovarian Cancer Therapeutics - Disease Overview

3 Ovarian Cancer Therapeutics - Market Characterization

4 Ovarian Cancer Therapeutics - Opportunity and Unmet Need

5 Ovarian Cancer Therapeutics - Competitive Assessment

6 Ovarian Cancer Therapeutics - Strategic Assessment

7 Product Profiles for the Major Marketed Products in the Ovarian Cancer Market

8 Ovarian Cancer - Pipeline Assessment

9 Ovarian Cancer Therapeutics - Clinical Trials Mapping

10 Ovarian Cancer Therapeutics - Future Market Players

11 Ovarian Cancer Therapeutics - M&A Analysis

12 Ovarian Cancer Therapeutics - Expert Opinion

13 Ovarian Cancer Therapeutics - Appendix

Companies Mentioned

F. Hoffmann-La Roche Ltd.

Menarini Group

GlaxoSmithKline plc.

Eisai Inc.,

Cell Therapeutics, Inc.

Amgen Inc.

AstraZeneca PLC

Boehringer Ingelheim GmbH

Oasmia Pharmaceutical AB

Endocyte, Inc.

BioNumerik Pharmaceuticals, Inc.

For more information visit http://www.researchandmarkets.com/research/c2ndz3/ovarian_cancer_the

Source: GlobalData

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): 353-1-481-1716
Sector: Oncology

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): 353-1-481-1716
Sector: Oncology